Transaction #32985 · Form 4 · 0001193125-26-420639
AN2 Therapeutics, Inc. · Stock award · Common Stock
AN2 Therapeutics, Inc. · Transacted October 12, 2026 · Filed October 13, 2026
What does this filing report?
An SEC Form 4 filing for AN2 Therapeutics, Inc. records a stock award involving Common Stock on October 12, 2026. The reported quantity was 2,465. The filing date is October 13, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- AN2 Therapeutics, Inc.
- Company CIK
- 0001880438
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 2,465
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 61,571
- Ownership description
- Not reported
- SEC acceptance time
- Oct 13, 2026, 5:12 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Aziz Kabeer ↗
Director
CIK 0001914847
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
- F2
- Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
- F3
- Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.